While Lrp10−/−;OT-1 cells persisted in the peripheral blood at higher levels 1 month after tumor rejection (Fig. EV5E), all mice in both treatment groups were able to resist a subsequent challenge with B16-ova cells. Here, LRP10 is linked to neoplasm.